- Home
- XHR vs PCRX Comparison
XHR vs PCRX Comparison
Compare XHR & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XHR
- PCRX
- Stock Information
- Founded
- XHR 2007
- PCRX 2006
- Country
- XHR United States
- PCRX United States
- Employees
- XHR N/A
- PCRX N/A
- Industry
- XHR Real Estate Investment Trusts
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- XHR Real Estate
- PCRX Health Care
- Exchange
- XHR Nasdaq
- PCRX Nasdaq
- Market Cap
- XHR 1.3B
- PCRX 1.2B
- IPO Year
- XHR N/A
- PCRX 2011
- Fundamental
- Price
- XHR $13.26
- PCRX $22.55
- Analyst Decision
- XHR Hold
- PCRX Buy
- Analyst Count
- XHR 6
- PCRX 8
- Target Price
- XHR $13.58
- PCRX $28.38
- AVG Volume (30 Days)
- XHR 1.2M
- PCRX 565.4K
- Earning Date
- XHR 08-01-2025
- PCRX 08-05-2025
- Dividend Yield
- XHR 4.23%
- PCRX N/A
- EPS Growth
- XHR 16.62
- PCRX N/A
- EPS
- XHR 0.22
- PCRX N/A
- Revenue
- XHR $1,060,486,000.00
- PCRX $702,772,000.00
- Revenue This Year
- XHR $3.27
- PCRX $7.92
- Revenue Next Year
- XHR $3.26
- PCRX $11.02
- P/E Ratio
- XHR $60.53
- PCRX N/A
- Revenue Growth
- XHR 3.57
- PCRX 3.08
- 52 Week Low
- XHR $8.55
- PCRX $11.16
- 52 Week High
- XHR $16.50
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- XHR 58.79
- PCRX 43.85
- Support Level
- XHR $13.11
- PCRX $21.26
- Resistance Level
- XHR $13.38
- PCRX $22.95
- Average True Range (ATR)
- XHR 0.31
- PCRX 0.83
- MACD
- XHR -0.01
- PCRX 0.01
- Stochastic Oscillator
- XHR 84.31
- PCRX 48.68
About XHR Xenia Hotels & Resorts Inc.
Xenia Hotels & Resorts Inc is a real estate investment trust that invests in premium full-service, lifestyle, and urban upscale hotels and resorts across the United States. The company owns and pursues hotels in the upscale, upper upscale, and luxury segments that are affiliated with various brands. Its hotels are operated by Marriott, along with Hilton, Hyatt, Starwood, Kimpton, Aston, Fairmont, and Loews. The firm's properties are located in various regions across the U.S.: the South Atlantic, West South Central, Pacific, Mountain, and other. Xenia's revenue is divided between room, food and beverage, and other. The firm's customer groups include transient business, group business, and contract business.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.